Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose-Escalation Study of LY2603618 with Gemcitabine in Japanese Patients with Solid Tumors
jRCT2080221454Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rabusertib in Nonhematologic neoplasms (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY2603618 in combination with gemcitabine.
02
Drugs
rabusertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221454.